Promising results for drug candidate CS1

Robyn Kalda
Jul 13
1 min read

This press release reports that over the 12 months of their Expanded Access Program enrolling ten patients, the majority of patients with pulmonary arterial hypertension who completed treatment with drug candidate CS1 maintained or improved their functional and biomarker status, and that CS1 showed a favourable safety and tolerability profile. A Phase IIb trial for CS1 begins this summer.

Read the Cereno Scientific press release

Recent Posts

In PAH, palliative care discussions need to be proactive

A survey of 200 people in the United States living with pulmonary arterial hypertension (PAH) found that 85% had never discussed palliative care with their healthcare provider, even though nearly nine

Endoplasmic reticulum stress induces a pathway that accelerates PAH progression

This study found that endoplasmic reticulum stress in lung blood vessels may contribute to pulmonary arterial hypertension (PAH) by triggering pyroptosis and damaging blood vessels. In rats, blocking

Phase 3 ADVANCE OUTCOMES trial on ralinepag succeeds

Patients with pulmonary arterial hypertension who took ralinepag in addition to their usual treatment were less likely to have their disease get worse than those who took a placebo. However, more peop

Comments